



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900
Email: nandita.singh@jagsonpal.com
CIN No.: L74899DL1978PLC009181

Date: May 30th, 2022

To, The Department of Corporate Services- Listing Bombay Stock Exchange Ltd, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001	To, National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
Scrip Code: 507789	Symbol: JAGSNPHARM

**Sub: Annual Secretarial Compliance Report for the financial year ended 31st March, 2022
under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements
Regulations, 2015.**

Dear Sir,

Pursuant to Regulation 24 A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2022

This is for your information and records.

Thanking You,

For JAGSONPAL PHARMACEUTICALS LIMITED

Nandita Singh
Company Secretary and Compliance Officer

Encl. as above



Secretarial Compliance Report
of Jagsonpal Pharmaceuticals Limited for the year ended 2021-22

We **Mukesh Arora & Co.**, practicing Company Secretaries have examined:

- (a) all the documents and records made available to us and explanation provided by Jagsonpal Pharmaceuticals Limited ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 2021-22 in respect of compliance with the provisions of:

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include: -

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **not applicable on relevant Financial year 2021-22**
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
The company has received an open offer for acquisition of upto 68,11,480 (Sixty Eight Lakhs Eleven Thousand Four Hundred Eighty) fully paid-up equity shares of face value of ₹ 5 each ("equity shares") representing 26.00% of the fully diluted voting equity share capital ("voting share capital"). The company has complied with the provisions of the SEBI (SAST) Regulations, 2011 regarding the open offer.
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **not applicable on relevant financial year 2021-22.**



- (e) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **not applicable on relevant financial year 2021-22.**
- (f) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations 2021; **not applicable on relevant financial year 2021-22.**
- (g) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (h) Any other regulations as applicable and circulars/ guidelines issued thereunder;

And based on the above examination, we hereby report that, during the Review Period:

The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below: -

Sr. No	Compliance Requirement (Regulations/ circulars / guidelines including specific clause)	Deviations	Observations/ Remarks of the Practicing Company
	N. A	-	-
	N. A	-	-

- (a) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder in so far as it appears from our examination of those records.
- (b) The following are the details of actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:



Sr. No.	Action taken by	Details of violation	Details of action taken E.g. fines, warning letter, debarment, etc.	Observations/ remarks of the Practicing Company Secretary, if any. (PAID)
	BSE/NSE	NIL	-	-

(c) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations of the Practicing Company Secretary in the previous	Observations made in the secretarial compliance report for the year ended... (The years are to be mentioned)	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
	N.A.	N.A.	-	-
	N.A.	N.A.	-	-

Disclaimer: Secretarial Compliance Report is issued on the bases of information/ records provided by the company. We further state that such compliance is neither an assurance as to the future viability of the company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

Place: Delhi
Date: 30-05-2022

FOR MUKESH ARORA & CO.


MUKESH ARORA
PRACTISING COMPANY SECRETARY
FCS No.: 4819
CP No.: 4405
UDIN NO: F004819D000433379